Table 1.

Effect of RAGE knockdown or decoy inhibition via sRAGE on total (intravascular plus extravascular) leukocyte presence at 10 h reperfusion

	RAGE Knockdown (AS-ODN Relative to MS-ODN)	RAGE Decoy Inhibition (sRAGE Relative to Vehicle)
Diabetic
Intact	↓70%*	↓81%*
OVX	↑11%†	↓38%†
OVE	↓86%*	↓88%*
Nondiabetic
Intact	↓19%†	not tested
OVX	↑14%†	not tested
OVE	↑11%†	not tested

RAGE, receptor for advanced glycation end products; sRAGE, soluble RAGE; AS, antisense, MS, missense; ODN oligodeoxynucleotide; OVX, ovariectomized; OVE, 17β-estradiol-replaced OVX.

^*P < 0.05 AS-ODN vs. MS-ODN or sRAGE vs. vehicle (diabetic and nondiabetic data derived from results summarized in Figs. 5 and 7, respectively).

^†Not significant.